Form 4: Korro Bio Director Rachel Meyers Reports Stock Option Grant

Director Rachel Meyers reports acquisition of stock options in Korro Bio, Inc.

Summary

• Rachel Meyers, a director of Korro Bio, Inc., filed a Form 4 on June 12, 2024, reporting a transaction.
• On June 11, 2024, Meyers acquired stock options for 5,190 shares of Korro Bio common stock at an exercise price of $42.19.
• The options vest fully on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, contingent upon continued service as a non-employee director.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It suggests confidence but doesn't provide substantial new information.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of compensation in publicly traded companies.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry, often used to align the interests of directors with those of shareholders.
• The vesting schedule described is typical, with vesting tied to continued service and/or company milestones.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, incentivizing them to work towards increasing the company's value.

Key Dates